Pr Philippe Moreau
- Spécialité
- Hématologue, expert myélome multiple
- Hôpital
- Centre Hospitalier Universitaire de Nantes
- Derniers articles
-
- Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma. (2 juil. 2026)
- Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma. (2 juil. 2026)
- Erratum to: "Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial". (1 juil. 2026)
- Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone. (27 juin 2026)
- A plain language summary describing how talquetamab affects the way people with multiple myeloma feel and function in the MonumenTAL-1 study. (16 juin 2026)